Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Long-Term Debt Repayments (2018 - 2019)

X4 Pharmaceuticals' Long-Term Debt Repayments history spans 2 years, with the latest figure at $6.5 million for Q3 2019.

  • For Q3 2019, Long-Term Debt Repayments rose 1190.8% year-over-year to $6.5 million; the TTM value through Dec 2020 reached $6.5 million, down 45.46%, while the annual FY2023 figure was $2.1 million, 159.62% up from the prior year.
  • Long-Term Debt Repayments reached $6.5 million in Q3 2019 per XFOR's latest filing, up from $4.9 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $6.5 million in Q3 2019 to a low of $500000.0 in Q1 2018.